Author Archives: Jan De Backer

FRI shows clinically meaningful benefits of Bevespi in COPD

We are happy to announce that a few days ago the positive results of AstraZeneca’s Bevespi (LABA/LAMA), compared to placebo have been published in the International Journal of COPD. The study shows how FRI confirmed the strong, homogeneous effect of the innovative co-suspension bronchodilator compared to placebo, as seen in earlier studies. At the same… Continue Reading

FRI and disease characterization: Idiopathic pulmonary fibrosis

A thorough understanding of a pharmaceutical company’s target disease is imperative when it wants to successfully develop and market its respiratory drug. Often, conventional lung function parameters lack the sensitivity and level of detail to fully capture a disease and this leads to very expensive developments in the respiratory field. This is especially the case in… Continue Reading

How is FRI a solution to your research question?

How is FRI a solution to your research question?

  We’ve said it before: the respiratory field is the most expensive one in the pharmaceutical world. The low sensitivity of several clinical biomarkers make it difficult for therapy developers to limit the size of their trails. Similarly, in the clinical domain, high costs occur among others from insensitive or difficult measurements, late detection of… Continue Reading

I:E and breathing control in CF drug delivery – what makes or breaks treatment?

  Cystic fibrosis (CF) is a devastating, chronic disease that affects over 100,000 people worldwide. The consequences patients need to bear with them for the rest of their lives are even more devastating. A CF patient is signed for continuous care, daily treatments, hours of daily physiotherapy sessions and regular hospital check-ups or visits, next… Continue Reading

FDA to support FLUIDDA’s FRI technology in the quest for more affordable drugs

The US Food and Drug administration has issued a letter of support to FLUIDDA after examination of study results where Functional Respiratory Imaging was used to assess bio-equivalence between a generic and a reference drug. Manufacturers of generic drugs are required to demonstrate that their drugs are therapeutically equivalent to the reference drug before they… Continue Reading

UCSF and FLUIDDA enter into a new research collaboration

Los Angeles, January 5th 2018 FLUIDDA Inc and the University of California, San Francisco (UCSF) are entering into a new research collaboration as of December 2017. Together with the team of Dr. John Fahy (Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Department of Medicine and investigator in the Cardiovascular Research… Continue Reading

FLUIDDA opens office in Los Angeles, CA

The opening of an office in Los Angeles (West Hollywood), California, marks the further expansion of FLUIDDA’s global presence. With an increasing number of clients located at the US West Coast, the California office allows FLUIDDA to provide an even better customer experience. “The high concentration of pharmaceuticals and medical device companies, as well as… Continue Reading